Peer Review reports
From: Real-world evidence of galcanezumab for migraine treatment in Japan: a retrospective analysis
| Original Submission | ||
|---|---|---|
| 2 Aug 2022 | Submitted | Original manuscript |
| Resubmission - Version 2 | ||
| Submitted | Manuscript version 2 | |
| 24 Aug 2022 | Reviewed | Reviewer Report |
| 3 Oct 2022 | Reviewed | Reviewer Report |
| 16 Nov 2022 | Author responded | Author comments - Tsubasa Takizawa |
| Resubmission - Version 3 | ||
| 16 Nov 2022 | Submitted | Manuscript version 3 |
| 22 Nov 2022 | Author responded | Author comments - Tsubasa Takizawa |
| Resubmission - Version 4 | ||
| 22 Nov 2022 | Submitted | Manuscript version 4 |
| 8 Dec 2022 | Reviewed | Reviewer Report |
| 14 Dec 2022 | Author responded | Author comments - Tsubasa Takizawa |
| Resubmission - Version 5 | ||
| 14 Dec 2022 | Submitted | Manuscript version 5 |
| 20 Dec 2022 | Reviewed | Reviewer Report |
| Resubmission - Version 6 | ||
| Submitted | Manuscript version 6 | |
| Publishing | ||
| 21 Dec 2022 | Editorially accepted | |
| 31 Dec 2022 | Article published | 10.1186/s12883-022-03041-1 |
You can find further information about peer review here.